SGLT2 Inhibitors: diabetes or cardiovascular drugs?

27 August 2018 (13:15 - 13:25)

Organised by:

About the speaker

Professor Lawrence Leiter

University of Toronto, Toronto (Canada)

6 More presentations in this session

Presentation thumbnail

Welcome and opening remarks.

Professor D. McGuire (Dallas, US)

Presentation thumbnail

Diabetes takes a center stage in overall risk for patients with cardiovascular disease .

Doctor A. Gitt (Ludwigshafen, DE)

Presentation thumbnail

Ertugliflozin – A newly emerging SGLT2 inhibitor for patients with type 2 diabetes.

Doctor S. Dagogo-Jack (Memphis, US)

Presentation thumbnail

Questions & Answers.

Professor D. McGuire (Dallas, US) Doctor S. Dagogo-Jack (Memphis, US) Doctor A. Gitt (Ludwigshafen, DE) Professor L. Leiter (Toronto, CA)

Presentation thumbnail

Envisioning the future of SGLT2 inhibitors in the treatment of patients with diabetes and cardiovascular disease: a roundtable discussion.

Doctor A. Gitt (Ludwigshafen, DE) Professor L. Leiter (Toronto, CA) Professor D. McGuire (Dallas, US) Doctor S. Dagogo-Jack (Memphis, US)

Access the full session

Session thumbnail

Five things cardiologists should know about diabetes

The Event

ESC Congress 2018

27 August 2018 13:15 CET

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources